NETAG issues updated appraisal and recommendation on ulipristal (ellaOne®) for post-coital contraception

Source: NETAG Area: Evidence > Drug Specific Reviews Ulipristal (ellaOne®) for post-coital 'emergency' contraception was previously considered and recommended by the NHS North East Treatment Advisory Group (NETAG) in October 2009. The Group has however completed a re-appraisal due to new clinical evidence and a specific wish to expand the use of ulipristal to patient groups which are not covered by the existing recommendation.   NETAG has not opted to change its previous recommendation following the updated appraisal. Ulipristal (ellaOne®) is therefore still recommended as the preferred drug treatment option for post-coital contraception for patients who present between 72 and 120 hours following unprotected intercourse. Levonorgestrel is still recommended for patients who present at up to 72 hours following unprotected intercourse. The group does not recommend ulipristal for any specific patient groups. When considering ulipristal, patients should be advised of the requirement for additional barrier contraception until ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news